The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Pastan, Ira H.
Wei, Junxia
Onda, Masanori
Bera, Tapan
Ho, Mitchell
Abstract
Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 14/21 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
2.
ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Liu, Qing-Rong
Zhu, Min
Egan, Josephine M.
Abstract
Methods of treating a subject with diabetes or Alzheimer's disease with a disclosed islet amyloid polypeptide (IAPP) isoform or peptide are provided. Methods of detecting IAPP isoforms or peptides are also provided.
A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
3.
METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Lu, Yong-Chen
Fitzgerald, Peter
Zheng, Zhili
Rosenberg, Steven A.
Abstract
Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Khristov, Vladimir R.
Charles, Steven T.
Amaral, Juan A.
Maminishkis, Arvydas
Bharti, Kapil
Abstract
A surgical clamp for aligning the margins of incised or wounded tissue has jaws with parallel clamping faces, and a handle for manipulating the clamp to align the margins of the tissue. The jaws are in a normally closed position, however they can be opened by compressing the handle to open the jaws. Prongs project from the inferior surface of the jaws. The clamp is positioned in a desired position over the margins of a wound to be closed, the prongs engage the margins of the wound to be aligned, and the jaws are closed by releasing compressive force on the handle. As the jaws close the prongs help move the tissue into alignment. Suture guide slots through the jaws assist in the placement of precisely placed sutures across the incision. The disclosed surgical clamp is particularly suited for selectively closing and reopening surgical incisions, such as a sclerotomy incision in the eye. Methods are disclosed for using the clamp during intraocular and other surgical or minimally invasive procedures. In one example the clamp is used during implantation into the retina of a scaffold on which choroid and retinal pigment epithelium cells and retina grow in a three-dimensional matrix that mimics the native structure of the retina.
A61B 17/04 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for suturing wounds; Holders or packages for needles or suture materials
6.
MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (USA)
KUROME THERAPEUTICS, INC. (USA)
Inventor
Hoyt, Scott, Bryan
Starczynowski, Daniel, T.
Thomas, Craig, Joseph
Rosenbaum, Jan, Susan
Abstract
The present disclosure provides pyrazolo[1,5-a]pyrimidine compounds and compositions comprising the same which inhibit IRAK and/or FLT3. The present disclosure further provides methods of using the pyrazolo[1,5-a]pyrimidine compounds to treat a disease or disorder such as a hematopoietic cancer, myelodysplastic syndromes (MDS), or acute myeloid leukemia (AML). Additional embodiments provide disease treatment using combinations of the disclosed IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Ramasawmy, Rajiv
Campbell, Adrienne Elizabeth
Javed, Ahsan
Herzka, Daniel
Abstract
A method and system for acquiring free-breathing magnetic resonance (MR) images are provided. The method utilizes a "free" navigator signal acquired by measuring MR signals during or following a slice select ramp down portion of an MRI pulse sequence. After processing the captured navigator signal with sampling-based and temporal filters, the resulting processed navigator signal may include information that correlates strongly with a respiratory cycle of a subject being imaged. Such navigator signal can be used retroactively to process the MRI image data to improve the image quality or resolve respiratory motion. This type of navigator signal can be used to allow fee-breathing of the subject during image acquisition, improving the comfort of the subject, while not significantly increasing the overall image capture time of many common MRI sequence.
C07C 235/14 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
C07C 275/18 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/26 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
C07D 265/10 - 1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
C07D 275/04 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Orentas, Rimas J.
Pastan, Ira H.
Dimitrov, Dimiter S.
Mackall, Crystal L.
Abstract
The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Orentas, Rimas J.
Pastan, Ira H.
Dimitrov, Dimiter S.
Mackall, Crystal L.
Abstract
The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
12.
ENGINEERED SARS-COV-2 ANTIBODIES WITH INCREASED NEUTRALIZATION BREADTH
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Misasi, John Nicholas
Wang, Lingshu
Sullivan, Nancy J.
Mascola, John R.
Choe, Misook
Zhou, Tongqing
Kwong, Peter D.
Koup, Richard Alan
Shi, Wei
Yang, Eun Sung
Zhang, Yi
Chen, Man
Abstract
Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies. In some embodiments, the SARS-CoV-2 is the BA.4 or BA.5 variant.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Ho, Mitchell
Duan, Zhijian
Hinrichs, Christian S.
Abstract
HHH) antibody libraries by panning the library with an E6- or E7-derived peptide in complex with HLA-A*02:01. Use of the single-domain antibodies for the detection and treatment of HPV-associated cancers and pre-cancerous lesions is also described.
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (USA)
THE GOVERNMENT OF THE UNITED STATES, as represented BY THE SECRETARY OF THE ARMY (USA)
SANOFI (France)
UNITED STATES OF AMERICA, as represented BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Joyce, Michael Gordon
Modjarrad, Kayvon
Thomas, Paul
Chen, Wei-Hung
Hajduczki, Agnes
Rolland, Morgane
Lewitus, Eric
Anosova, Natalie
Clark, Nicholas
Davidson, Philip
Lecouturier, Valerie
Ustyugova, Irina, V.
Warren, William
Wu, Monica, Z.
Douek, Daniel
Koup, Richard
Abstract
The present disclosure relates to the field of vaccines and binding molecules, as well as preparations and methods of their use in the treatment and/or prevention of disease. Described are vaccines and binding molecules, compositions containing the same, and uses thereof for treating or preventing coronavirus infections, including multivalent mRNA and nanoparticle vaccines.
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
15.
SYSTEMS AND METHODS FOR ELECTROCARDIOGRAPHIC RADIAL DEPTH NAVIGATION OF INTRACARDIAC DEVICES
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Lederman, Robert J.
Bruce, Christopher G.
Yildirim, Dursun Korel
Abstract
Various systems and methods are provided for electrocardiographic radial depth navigation for intracardiac device insertion into a heart. In one example, a method includes acquiring an intracardiac electrogram signal via an electrode of an intracardiac device during insertion of the intracardiac device into a heart muscle or chambers and outputting a radial depth indication with respect to myocardium of the heart based on electronic processing of the intracardiac electrogram signal.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
16.
SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Felber, Barbara, K.
Pavlakis, George, N.
Karaliota, Sevasti
Stellas, Dimitrios
Abstract
This disclosure provides compositions and methods comprising combinations of IL-15 or an I L-15/IL-15Ra complex with one or more other active agents for the treatment of cancer. This disclosure also provides compositions and methods comprising combinations of IL-15 or an IL-15/I L-15Rct complex fused to IL-12 or a derivative thereof, and with one or more other active agents for the treatment of cancer. In some embodiments, the one or more active agents comprises an activator of PPAR. In some embodiments, the one or more active agents comprises inhibitor of FLT3. In some embodiments, the one or more active agents comprises a chemotherapeutic agent.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Lusso, Paolo
Zhang, Peng
Abstract
The invention provides an HIV-1 Env-derived immunogen that simultaneously engages more than one lineage of germline bNAbs specific for different neutralization target sites of the native HIV-1 Env trimer. In certain embodiments, the inventive immunogen comprises a chimeric Env, with binding sites drawn from more than one native Env proteins. These can be used both in the form of full-length/minimally truncated membrane-bound trimers (e.g., expressed from cDNA, mRNA or viral vectors, which also are provided by the present invention, as are cells comprising the immunogen) or, alternatively, in the form of soluble truncated trimers (e.g., SOSIP or IP trimers). Also provided are a pharmaceutical composition comprising the inventive immunogen, nucleic acids encoding the same, and/or cells comprising them, and a method of vaccinating a human patient against HIV using the inventive immunogen and composition.
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
AEVISBIO, INC. (USA)
Inventor
Greig, Nigel, H.
Luo, Weiming
Tweedie, David
Scerba, Michael, T.
Lecca, Daniela
Hsueh, Shih Chang
Kim, Dong Seok
Abstract
Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to a subject with a traumatic brain injury, an inflammatory disorder, an autoimmune disorder, a neurodegenerative disease, a viral infection, or any combination thereof. The disclosed halophthalimides have a structure according to Formula (I), or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof,
C07D 209/48 - Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
19.
SURGICAL TOOL AND METHOD FOR SOFT OCULAR TISSUE TRANSPLANTATION
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Maminishkis, Arvydas
Abstract
Disclosed are devices and methods for delivering a sheet of tissue into the eye in such a way that damage to the tissue is minimized, damage to the eye during insertion and manipulation of the tissue is minimized, and the tissue is released and delivered in a precise and controlled fashion.
A61F 9/00 - Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
20.
MONOCLONAL ANTIBODIES THAT BIND TO THE UNDERSIDE OF INFLUENZA VIRAL NEURAMINIDASE
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Kanekiyo, Masaru
Lederhofer, Julia
Tsybovsky, Yaroslav
Andrews, Sarah F.
Abstract
Monoclonal antibodies are antigen binding fragments are disclosed that specifically bind to the underside of influenza A neuraminidase (NA). In some aspects, these antibodies and antigen binding fragments are used for in methods of treating a subject with an influenza A infection, such as an H3N2 infection. In more aspects, these antibodies and antigen binding fragments and bispecific antibodies for detection of an influenza virus in a sample, and for selecting vaccines.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (USA)
KUROME THERAPEUTICS, INC. (USA)
Inventor
Thomas, Craig, Joseph
Hoyt, Scott, Bryan
Starczynowski, Daniel, T.
Rosenbaum, Jan, Susan
Bennett, Joshua
Abstract
The present disclosure provides a method of treating an inflammatory disease/disorder, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) in a subject comprising administering to the subject a compound that inhibits IRAKI and IRAK4. The present disclosure further provides a method of determining a compound that is effective at treating an inflammatory disease/disorder, AML, or MDS.
C07D 471/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains two hetero rings
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Tolia, Niraj Harish
Patel, Palak Narendra
Dickey, Thayne Henderson
Miura, Kazutoyo
Long, Carole Ann
Abstract
The present disclosure relates to vaccines, therapeutic antibodies and methods of making such vaccines and antibodies. More specifically, the disclosure relates to methods of immunofocusing an immune response to a protein having both neutralizing epitopes and non-neutralizing epitopes, such that the immune response is preferentially, or completely, directed towards, or away from, a particular portion of the antigen. The disclosure also relates to methods of using the disclosed vaccines and immunofocused proteins to vaccinate an individual and to detect neutralizing antibodies in a sample from an individual.
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Rice, Kenner Cralle
Jacobson, Arthur, E.
Sulima, Agnieszka
Chambers, Dana, Rae
Roth, Hudson, Gordon
Abstract
Compounds having opioid characteristics are provided that can be used for various therapeutic methods including the treatment of pain and opioid use disorders, and compounds having opioid antagonist properties that can be used to treat opioid overdoses. These compounds include agonists and antagonists having selective activity toward more one or more opioid receptors. Such compounds can be full or partial agonists, or can be antagonists lacking agonist properties toward delta and kappa opioid receptors. The partial agonists can diminish side effects associated with traditional opioid medications, and the antagonists can overcome respiratory depression caused by potent narcotics. Structurally these compounds include constrained piperidines with alkenyl or cyanoalkyl groups, as well as other substituents providing desired properties.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
O'Keefe, Barry, R.
Du, Lin
Wilson, Brice, A. P.
Zhang, Ping
Wang, Dongdong
Martinez Fiesco, Juliana
Li, Ning
Moore, William J.
Abstract
Disclosed is a class of kinase inhibitors. Related pharmaceutical compositions and methods of making and using the kinase inhibitors are also disclosed.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Love, Paul E.
Gaud, Guillaume
Hinrichs, Christian S.
Davies, John S.
Abstract
Disclosed is a cell expressing a modified CD3 subunit chain or a cell expressing a modified non-CD3 subunit chain comprising one or more of: (a) at least one Immuno-receptor Tyrosine-based Activation Motif (ITAM) deletion; or (b) at least one exogenous intracellular hematopoietic cell signaling domain; and (c) at least one modified ITAM comprising an amino acid sequence of Formula I. Related populations of cells, pharmaceutical compositions, methods of making the cells, methods of treating or preventing a condition in a subject, and methods of enhancing an antigen-specific immune response in a subject are also disclosed.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Sun, Peter D.
Erickson, Rachel
Abstract
Methods of treating or inhibiting viral infection-induced airway fibrosis in a subject, the method including administering to the subject an effective amount of a composition including one or more direct thrombin inhibitors or one or more serine protease inhibitors or metalloprotease inhibitors are provided. In some examples, the composition is administered to the subject by inhalation. In particular examples, the viral infection-induced airway fibrosis is a coronavirus infection-induced airway fibrosis.
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 38/58 - Protease inhibitors from humans from leeches, e.g. hirudin, eglin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 11/00 - Drugs for disorders of the respiratory system
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Tolia, Niraj H.
Ma, Rui
Duffy, Patrick E.
Renn, Jonathan P.
Abstract
The disclosure provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum. Aspects of the disclosed immunogen polypeptides comprise all or portions of the CSA binding regions of VAR2CSA as identified by a structural study of VAR2CSA conducted by the inventors. Also provided are compositions comprising such immunogen polypeptides, and methods of using the immunogen polypeptides for vaccination and treatment of disease.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Felber, Barbara K.
Pavlakis, George N.
Abstract
This disclosure generally relates to methods and compositions for eliciting broad and robust immune responses to a protein of interest. The methods employ both DNA and RNA-based vaccines that encode at least a portion of the protein of interest.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Sadtler, Kaitlyn Noelle
Lokwani, Ravi
Ngo, Tran
Abstract
The present disclosure relates to compositions and methods for improving wound healing and tissue regeneration. More specifically, the present disclosure relates to compositions, and methods of using such compositions, that direct the immune response within a wound towards a pro-regenerative response. Such compositions and methods are particularly useful in altering the immune response elicited by medical implants, to avoid scarring and fibrosis at the site of implantation.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
NISSUI CORPORATION (Japan)
Inventor
Yang, Zhi-Hong
Remaley, Alan Thomas
Rojulpote, Krishna Vamsi S.
Tang, Jingrong
Yamazaki, Isao
Yamaguchi, Hideaki
Sato, Seizo
Abstract
The present invention is directed to methods for treating macular degeneration, atherosclerosis, fatty liver, obesity, and cognitive ability, and more specifically to methods for treating macular degeneration, atherosclerosis, fatty liver, obesity, and cognitive ability using very long chain polyunsaturated fatty acids having 24 to 40 carbon atoms.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
WASHINGTON UNIVERSITY (USA)
Inventor
Cunningham, Lisa Lynn
Sung, Cathy Yea Won
Warchol, Mark E.
Abstract
Disclosed is a method of impeding platinum-based chemotherapeutic induced ototoxicity, and/or other toxicity, the method comprising administering a colony stimulating factor 1 receptor (CSF1R) inhibitor to a subject in an amount sufficient to impede ototoxicity, and/or other toxicity, inducible by a platinum-based chemotherapeutic; and administering the platinum-based chemotherapeutic to the subject. The CSF1R inhibitor can be, for example, pexidartinib. The platinum-based chemotherapeutic can be, for example, cisplatin. Compositions, medicaments, kits, and uses are disclosed related to the same. Further, a method of screening for a compound able to impede a platinum-based chemotherapeutic induced toxicity is disclosed.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
O'Keefe, Barry R.
Haugh Krumpe, Lauren R.
Pommier, Yves
Marchand, Christophe R.
Schroeder, Ingrid C.
Rosengren, K. Johan
Wilson, Brice A.P.
Abstract
Disclosed is a class of knotted cyclic peptides. Related pharmaceutical compositions and methods of using the peptides and methods of synthesizing the peptides are also disclosed.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Li, Juan
Wei, Chi-Jen
Wei, Ronnie R.
Yang, Zhi-Yong
Mascola, John R.
Nabel, Gary J.
Misasi, John
Pegu, Amarendra
Wang, Lingshu
Zhou, Tongqing
Choe, Misook
Oloniniyi, Olamide K.
Zhao, Bingchun
Zhang, Yi
Yang, Eun Sung
Chen, Man
Leung, Kwanyee
Shi, Wei
Sullivan, Nancy J.
Kwong, Peter D.
Koup, Richard A.
Graham, Barney S.
He, Peng
Abstract
Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
36.
AUGMENTING MITOCHONDRIA IN IMMUNE CELLS FOR IMPROVED CANCER IMMUNOTHERAPY
LEIBNIZ-INSTITUT FÜR IMMUNTHERAPIE (LIT) (Germany)
THE BRIGHAM AND WOMEN'S HOSPITAL INC. (USA)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Gattinoni, Luca
Baldwin, Jeremy
Fioravanti, Jessica
Sengupta, Shiladitya
Saha, Tanmoy
Abstract
The present invention relates to compositions and methods in the context of mitochondrial transfer. Disclosed herein are methods that enable the efficient transfer of mitochondria from a donor cell to a recipient cell. The mitochondria-augmented cells are useful in the treatment of diseases and disorders, such as cancer. The present invention also relates to the molecular machinery involved in mitochondrial transfer.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Kobayashi, Hisataka
Choyke, Peter L.
Abstract
Monoclonal antibodies that specifically bind CD25, as well as conjugates of the anti-CD25 antibodies, are described. The CD25-specific monoclonal antibodies and conjugates thereof do not block binding of IL- 2 to CD25 and induce little to no antibody -dependent cellular cytotoxicity (ADCC). The anti- CD25 antibodies and conjugates can be used, for example, to target photoimmunotherapy to T regulatory (Treg) cells in tumor beds to enhance the local host immune response to the tumor.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
38.
ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Wei, Ronnie R.
Wei, Chi-Jen
Yang, Zhi-Yong
Mascola, John R.
Nabel, Gary J.
Misasi, John
Pegu, Amarendra
Wang, Lingshu
Zhou, Tongqing
Choe, Misook
Oloniniyi, Olamide K.
Zhao, Bingchun
Zhang, Yi
Yang, Eun Sung
Chen, Man
Leung, Kwanyee
Shi, Wei
Sullivan, Nancy J.
Kwong, Peter D.
Koup, Richard A.
Graham, Barney S.
Abstract
Disclosed are antigen binding antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptide complexes; and methods of using such polypeptide complexes.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Bulea, Thomas
Lerner, Zachary
Damiano, Diane
Gravunder, Andrew
Abstract
Disclosed are powered gait assistance systems that include a controller, sensors, and a torque applicator (motor, spring, etc.) coupled to a patient's hips, thighs, knee, lower leg, ankle, and/or foot and operable to apply assistive torque to the patient's leg joint(s) to assist the patient's volitional joint actuating muscle output during selected stages of the patient's gait cycle, such that the applied torque improves the patient's leg posture, muscle output, range of motion, and/or other parameters over the gait cycle. The sensors can include a torque sensor that measures torque applied, one or more joint angle sensors, a ground contact sensor that measures ground contact of the patient's foot, and/or other sensors. The controller can determine what stage of the patient's gait cycle the patient's leg is in based on sensor signals and cause the torque applicator to apply corresponding torque to the joint(s) based on the gait cycle stage, sensor inputs, and known patient characteristics.
A63F 13/212 - Input arrangements for video game devices characterised by their sensors, purposes or types using sensors worn by the player, e.g. for measuring heart beat or leg activity
A61H 1/02 - Stretching or bending apparatus for exercising
A61H 3/00 - Appliances for aiding patients or disabled persons to walk about
40.
MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (USA)
KUROME THERAPEUTICS, INC. (USA)
Inventor
Thomas, Craig, Joseph
Hoyt, Scott, Bryan
Starczynowski, Daniel, T.
Rosenbaum, Jan, Susan
Abstract
Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/4738 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
KUROME THERAPEUTICS, INC. (USA)
Inventor
Thomas, Craig, Joseph
Hoyt, Scott, Bryan
Starczynowski, Daniel, T.
Rosenbaum, Jan, Susan
Abstract
Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Wohlstadter, Jacob N.
Sigal, George
Wilbur, James
Debad, Jeffery
Biebuyck, Hans
Krai, Priscilla
Kishbaugh, Alan
Dzantiev, Leonid
Shelburne, Christopher
Campbell, Christopher
Aksyuk, Anastasia
Harkins, Seth B.
Fulkerson, John
Jakubik, Jocelyn Jean
Mcdermott, Adrian
O'Connell, Sarah
Narpala, Sandeep
Abstract
The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Mandecki, Wlodek
Goldman, Emanuel
Chudaev, Maxim
Henderson, Mark James
Marugan, Juan Jose
Ye, Wenjuan
Wilson, Kenneth
Parker, Dane
Abstract
Compounds and methods for their use in inhibiting bacterial protein synthesis in gram-positive bacteria and treating gram-positive bacterial infections in a subj ect are provided.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Hoang, Danh-Tai
Stone, Eric
Ruppin, Eytan
Dinstag, Gal
Aharonov, Ranit
Beker, Tuvik
Abstract
A method of training an artificial neural network to predict gene expression for a patient having a pathological condition is provided. The method comprises obtaining a set of histopathological images from a database of patients having the pathological condition, collecting from the database a set of gene expression profiles corresponding to the histopathological images, identifying in the set of gene expression profiles a set of considered genes, selecting a training subset of the considered genes comprising genes characterized by similar median gene expression values, and training the neural network to predict a gene expression value of an input histopathological image, using gene expression profiles of the genes in the training subset simultaneously.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Liang, Bruce T.
Verma, Rajkumar
Jacobson, Kenneth A.
Toti, Kiran S.
Abstract
Compositions and methods for the treatment of a human subject who has had a stroke or myocardial ischemia reperfusion injury, by administering to the subject a pharmaceutical composition including a compound of Formula (I) and/or of Formula (5) or a pharmaceutically acceptable salt and/or formulation thereof. The pharmaceutical composition can be administered in the acute phase of stroke, optionally in combination with a thrombolytic therapeutic or a procedure on the subject involving a clot-removal device.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/5395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
THE UNITED STATES OF AMERICA, AS represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Alzamzmi, Ghadh A.
Antani, Sameer K.
Hsu, Li-Yueh
Sachdev, Vandana
Rajaraman, Sivarama Krishnan
Abstract
An Artificial Intelligence (AI) system for estimating inferior vena cava (IVC) collapsibility and right atrial pressure (RAP) from an echocardiography study in real-time is provided. The system includes an image retrieval network that is configured to receive images from the echocardiography study and perform a quality assessment of the images to generate selected images. The system further includes a region segmentation network to localize and segment the selected images to obtain IVC regions in the selected images. The system further includes an IVC quantification and RAP estimation network to perform a distance calculation to find a diameter in the IVC regions at different spatial and temporal points, allowing a more reliable estimation of RAP values; and the system further includes an open-world active learning system comprising a classification engine and a clustering engine.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Raimondi, Giorgio
Schneider, Joel P.
Patrone, Julia
Komin, Alexander
Nambiar, Monessha
Calderon-Colon, Xiomara
Tiburzi, Olivia
Abstract
The present disclosure provides compositions, systems, devices, and methods for the delivery of therapeutics. Particularly, the disclosure provides composition, systems, and devices of the delivery of Janus kinase (JAK) inhibitors and uses thereof, such as for inhibiting allograft rejection or treating autoimmune diseases.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE JOHNS HOPKINS UNIVERSITY (USA)
INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (USA)
Inventor
Sauna, Zuben
Hernandez, Nancy
Jankowski, Wojciech
Gray, Jeffrey
Frick, Rahel
Kelow, Simon
Dunbrack, Roland
Abstract
This disclosure concerns antibodies that are computationally designed and engineered to specifically bind to the spike protein of SARS-CoV-2 strains and variants with high affinity. The disclosure also concerns uses of the antibodies for the detection, prophylaxis, and treatment of SARS-CoV-2 infection.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Yewdell, Jonathan Wilson
Kosik, Ivan
Abstract
Compounds for inhibiting the replication of intracellular microorganisms are described. More specifically, the present disclosure provides transbodies comprising a cell-penetrating moiety (CPM) and a binding moiety (BM). The CPM, which may be a cell-penetrating peptide (CPP), allows translocation of the entire transbody into a cell. The BM, which may comprise an antibody, binds a protein from an intracellular microorganism, thereby inhibiting replication of the intracellular microorganism. The disclosed transbodies may be used to inhibit replication of intracellular microorganisms in cells in culture, and/or they may be used to treat individuals infected with an intracellular microorganism.
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Nutman, Thomas B.
Bennuru, Sasisekhar
Abstract
,, are provided, including the antigen Wb5 or fusion proteins including Wb5 linked to a reporter protein or tag. Nucleic acids encoding the Wb5 protein or the fusion proteins, vectors including the nucleic acids, and host cells including the nucleic acids or vectors are also provided. Methods of detection of antibodies to Wb5 in a sample from a subject, including immunoassay methods are also provided.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Wang, Tony T.
Liu, Shufeng
Stauft, Charles B.
Selvaraj, Prabhuanand
Lien, Christopher Z.
Abstract
Engineered SARS-CoV-2 variants having a combination of attenuating modifications, and their use as live-attenuated SARS-CoV-2 vaccines, are described. The recombinant genome of the live-attenuated SARS-CoV-2 encodes a modified spike (S) protein with a deletion of the polybasic site (DPRRA); encodes a modified non-structural protein 1 (Nsp1) with K164A and H165A substitutions; and includes a mutation that prevents expression of open reading frames (ORFs) 6, 7a, 7b and 8. The disclosed live-attenuated SARS-CoV-2 retain the capacity to infect and replicate in mammalian cells. Immunogenic compositions that include a live-attenuated SARS-CoV-2 and methods of eliciting an immune response against SARS-CoV-2 in a subject are also described. Further disclosed are a collection of reverse genetics plasmids that include the complement of the recombinant genome of the live-attenuated SARS-CoV-2 and methods of producing a live-attenuated SARS-CoV-2 using the reverse genetics plasmids.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Venditti, Charles P.
Chandler, Randy
Abstract
The present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV) and methods of using such vectors and viruses in gene therapy for treating methylmalonic acidemia in patients with methylmalonyl-coA mutase (MVMUT) deficiency. Also provided are pharmaceutical compositions comprising recombinant adeno-associated virus (rAAV) and a pharmaceutically acceptable carrier or excipient.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
THE UNITED STATES OF AMERICA, as represented by the Secretary, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
HDT BIO (USA)
Inventor
Hawman, David
Feldmann, Heinz
Erasmus, Jesse Hong-Sae
Abstract
Described herein are constructs, compositions, and methods for eliciting an immune response against CCHFV. In particular, the disclosure relates to self-replicating RNAs expressing encoding at least one heterologous polypeptide comprising an epitope that elicits an immune response against CCHFV. The disclosure also relates to compositions and nanoparticles comprising the disclosed self-replicating RNAs, and the use of such nanoparticles and compositions to elicit an immune response against CCHFV in an individual, thereby protecting the individual from infection with CCHFV.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Lee, Kyung S.
Jacobson, Kenneth A.
Alverez, Celeste N.
Park, Jung-Eun
Oliva, Paola
Lee, Hobin
Pongorne Kirsch, Klara
Abstract
Provided is a method of treating cancer, particularly cancers associated with an overexpression of polo-like kinase (Plk1), comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof in which ring A, X1, X2, X3, X4, X5, R2, R3, R4, n, bond a, and bond b are described herein. Exemplary compounds of formula (I) and pharmaceutically acceptable salts thereof, especially those that selectively inhibit the polo box domain of Plk1, also are provided.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Franchini, Genoveffa
Sarkis, Sarkis
Moles, Ramona
Masison, Cynthia
Bissa, Massimiliano
Abstract
Provided herein is a nucleic acid-based vaccine for human T-cell leukemia virus type 1 (HTLV-1). In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HTLV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HIV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. When administered to a subject, the Env and Gag proteins are expressed in the host and form HTLV-1 virus-like particles (VLPs) that are secreted from cells within the host and elicit an immune response that inhibits HTLV-1 infection.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventor
Brognard, John F.
Swenson, Rolf E.
Torres-Ayuso, Pedro
Sabbasani, Venkatareddy
Mehlich, Dawid G.
Warfel, Noel A.
Abstract
Provided is a compound of formula (I) X1-L-X2(I), in which X1is a residue with an affinity for a Proviral Integration site for Moloney murine leukemia virus (PIM) kinase; L is a linker; and X2 is a residue with an affinity for a ubiquitin ligase. Further provided is a method of treating cancer in a mammal comprising administering to the mammal an effective amount of a compound of formula (I), in which the cancer comprises cancer cells that overexpress a PIM kinase relative to non‑cancerous cells of the same tissue type, such as prostate cancer. [formula II]
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Sauna, Zuben E.
Jankowski, Wojciech
Hernandez, Nancy E.
Abstract
Modified Factor Xa polypeptides having functional activity and reduced affinity for apixaban are provided. Nucleic acids encoding the modified Factor Xa polypeptides and vectors and host cells including the nucleic acids are also provided. Methods of reducing or inhibiting bleeding, such as in a subject being treated with a direct oral anticoagulant are provided.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Lederman, Robert J.
Kolandaivelu, Aravindan
Yildirim, Dursun Korel
Bruce, Christopher G.
Abstract
Various systems and methods are provided for cardiac resynchronization therapy. In one example, apparatus for a multi-electrode pacemaker lead, comprises a plurality of ring electrodes distributed along a length of the multi-electrode pacemaker lead, the multi-electrode pacemaker lead configured to be implanted within myocardium of a wall of a ventricle of a heart such that an outer surface defining a circumference of at least one of the plurality of ring electrodes is in direct contact with the myocardium.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
EUREKA THERAPEUTICS, INC. (USA)
Inventor
Ho, Mitchell
Li, Nan
Li, Dan
Liu, Cheng
Zhang, Hongbing
Yang, Zhiyuan
Abstract
Recombinant antibody T cell receptors (AbTCRs) and chimeric signaling receptors (CSRs) engineered to include antigen-binding domains specific for tumor antigen glypican-2 (GPC2) or glypican-3 (GPC3) are described. Immune cells expressing the AbTCRs and CSRs effectively treated GPC2-positive or GPC3-positive tumors in multiple different xenograft models, and were significantly more potent than similarly targeted chimeric antigen receptor (CAR) T cells.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Remaley, Alan T.
Reimund, Mart
Graziano, Giorgio T.
Sviridov, Denis
Dasseux, Amaury L.P.
Abstract
ApoE mimetic peptides of 8-17 amino acids long including the ApoE receptor binding region or a portion thereof, and one or more covalent linkages joining at least two non-contiguous amino acids of the peptide are provided. Methods of treating dyslipidemic disorders, such as hypertriglyceridemia or hypercholesterolemia, or viral infection using the peptides are also provided.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Sadtler, Kaitlyn Noelle
Fathi, Parinaz
Morgan, Nicole
Sangsari, Paniz Rezvan
Abstract
Fibrotic diagnostic systems, subsystems, and components thereof are provided. A fibrotic diagnostic system can comprise a microfluidic device. The fibrotic diagnostic system can be preloaded with one or more components. For example, the fibrotic diagnostic system can comprise the one or more reagents and a target object, for example a tissue, or a medical device, or both intended for implantation. The fibrotic diagnostic system can comprise one or more additional components and subsystems, for example, a detector comprising a sensor configured to detect fibrosis of the target object, a thermal subsystem, a fluidic subsystem, a processor, or a user interface, or any combination thereof. Kits comprising one or more components of a fibrotic diagnostic system are provided. Screening methods for identifying therapeutics are provided that utilize a fibrotic diagnostic system or component thereof are provided. Non-transitory computer-readable media storing a program are further provided.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Desai, Sanjay A.
Pillai, Ajay D.
Abstract
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I,
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I,
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I,
or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4741 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Liu, Yuanyuan
Lai, Xiaomin
Abstract
An imaging system and method includes a microscope for observing a sample. A light source is arranged to generate light along an optical path of the microscope. A lens array is positioned in the optical path of the microscope, the lens array having a plurality of lenses each with a lens optical axis, the lens optical axes positioned to each capture a separate field of view of the sample. At least one detector is configured to detect the separate fields of view from the lenses. The imaging system is configured to mosaic the detected separate fields of view from each lens to generate an image of the sample.
THE UNITED STATES OF AMERICA, as represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Nath, Avindra
Li, Wenxue
Sampson, Kevon
Shah, Ashish
Taylor, Naomi
Majdoul, Saliha
Abstract
The disclosure provides recombinant polypeptides that specifically bind to an envelope epitope of HERV-K HML-2, wherein such engineered polypeptides may be single-domain antibodies or immunoglobulin variable domains. The disclosure also provides CAR comprising such recombinant polypeptides. The disclosure further provides nucleic acid molecules that encode such recombinant polypeptides or CARs, and methods of making such recombinant polypeptides or CARs. The disclosure further provides pharmaceutical compositions that comprise such recombinant polypeptides or CARs, and methods of treatment using such recombinant polypeptides or CARs.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Pickens, Charles Austin
Petritis, Konstantinos
Abstract
A method of multiplexing Hcy and/or Cys in a first-tier screening assay includes: contacting a blood sample with a reducing agent optionally in the presence of a solvent to convert at least one of a Hcy dimer, a Hcy-protein complex, a Cys dimer different from the homocysteine dimer, or a Cys-protein complex in the blood sample to a Hcy and/or Cys monomer thereby forming a monomer sample; reacting the Hcy and/or Cys monomer in the monomer sample with a thiol derivatizing agent to form a thiol derivatized sample comprising a thiol derivatized Hcy and/or Cys monomer; and optionally converting a carboxylic acid or a carboxylate group in the thiol derivatized Hcy and/or Cys monomer to an ester, forming a thiol-and-ester derivatized sample comprising a thiol-and-ester derivatized Hcy and/or Cys monomer. The method can be used to determine a level of tHcy, a level of tCys, and/or a level of CysT in a blood sample, and screen for CBS deficiency, HCU, or hyperhomocysteinemia.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Sullivan, Nancy J.
Misasi, John N.
Bai, Ke
Asokan, Mangaiarkarasi
Leigh, Kendra
Pegu, Amarendra
Mascola, John R.
Demouth, Megan E.
Stringham, Christopher D.
Oloniniyi, Olamide K.
Abstract
A bispecific monoclonal antibody that specifically binds two distinct epitopes of the Ebola virus (EBOV) glycoprotein (GP) is described. The bispecific antibody is comprised of the antigen binding domains of GP-specific monoclonal antibodies mAb114 and S1-4-A09 ("A09"). The EBOV GP bispecific monoclonal antibody (mAb114xA09 or BiSp107) exhibits synergistic neutralization of pseudotyped virus expressing EBOV GP compared with the neutralization capacity of the combination of the individual parental antibodies. Methods for pre- and post-exposure prophylaxis and treatment are described.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Kim, Sanghyun
Zacharakis, Nikolaos
Rosenberg, Steven A.
Abstract
Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53R273C or human p53Y220C. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Swenson, Rolf E.
Ettedgui-Benjamini, Jessica H.
Cherukuri, Murali K.
Woodroofe Hitko, Carolyn
Raju, Natarajan
Abstract
Disclosed is a sterile MRI probe infusion device for preparing and administering a hyperpolarized MRI probe to a patient in need thereof. The device includes one or more reaction chambers, where a hyperpolarized MRI probe is prepared, separated from the reaction mixture, concentrated, and a solution of suitable concentration for administration to a patient is prepared. Also disclosed is a method of preparing and administering a hyperpolarized MRI probe by the use of the device to a patient in need thereof for diagnosing stages of a disease or an adverse condition or monitoring progress of a treatment of the patient having a disease or an adverse condition.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Swenson, Rolf E.
Ettedgui-Benjamini, Jessica H.
Woodroofe Hitko, Carolyn
Cherukuri, Murali K.
Raju, Natarajan
Abstract
mqq] or a salt thereof. Also disclosed is a method of preparing a hyperpolarized substrate comprising a ½ spin nucleus or nuclei using the perfluorinated SABRE catalysts, and isolating the resulting hyperpolarized substrate for administration to an animal. Further disclosed is a method of imaging a tissue of an animal suspected of having a disease or condition.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Ackerman, Hans Christian
Brooks, Steven David
Cruz, Phillip
Swenson, Rolf Eric
Abstract
123456123456 78978910111213141510111213141515 is any amino acid, wherein the isolated peptide is at most 75 amino acids in length. Molecules including these isolated polypeptides are disclosed, as well as nucleic acid molecules and vectors encoding these polypeptides. Pharmaceutical compositions including the polypeptides, molecules, nucleic acids and vectors are of use for increasing vascular nitric oxide bioavailability and/or inhibiting vasoconstriction in a subject.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Ishii, Kazusa
Hinrichs, Christian S.
Abstract
Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a CD20 amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Ding, Bangwei
Alimardanov, Asaf Ragim
Huang, Junfeng
Abstract
Methods of synthesizing (R)-N-(4-(4-(3-chloro-5-ethyl-2- methoxyphenyl) piperazin-l-yl)-3-hydroxybutyl)-l H-indole-2- carboxamide (compound 8) are described as well as intermediate compounds of formulae 5-7, 9 and 14 used in said methods.
C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
75.
MODIFICATION-DEPENDENT ENRICHMENT OF DNA BY GENOME OF ORIGIN
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Enam, Syed Usman
Fire, Andrew Z.
Lipman, David
Leonard, Susan
Cherry, Joshua L.
Zheludev, Ivan
Abstract
Compositions and methods are provided to enrich for DNA corresponding to a genome of interest, e.g. by species, clade, or strain of origin, from a mixed population of nucleic acid sequences. The methods may further comprise identification of the genomic sequences of interest, e.g. identifying the species, clade, strain, etc. of origin.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Kwong, Peter
Zhang, Baoshan
Damron, Leland
Bylund, Tatsiana
Pegu, Amarendra
Yang, Eun Sung
Gorman, Jason
Kwon, Young Do
Yang, Yongping
Doria-Rose, Nicole
Abstract
Bispecific antibodies that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these bispecific antibodies, vectors and host cells are also provided. In addition, the use of these bispecific antibodies, nucleic acid molecules, and vectors to prevent and/or treat an HIV-1 infection is disclosed.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
KWONG, Peter D. (USA)
Inventor
Mascola, John R.
Kwon, Young Do
Pegu, Amarendra
Yang, Eun Sung
Mckee, Krisha
Doria-Rose, Nicole
Abstract
Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Rudloff, Udo
Marugan, Juan Jose
Sable, Rushikesh Vilas
Henderson, Mark James
Calvo, Raul Ronaldo
Southall, Noel Terrence
Abstract
Methods for treating diabetic retinopathy and age-related macular degeneration (AMD), as well as pharmaceutical compositions relevant thereto are disclosed.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE MEDICAL COLLEGE OF WISCONSIN, INC. (USA)
Inventor
Jacobson, Kenneth A.
Fallot, Lucas B.
Ravi, Rama S.
Fisher, Courtney L.
Auchampach, John A.
Salmaso, Veronica
Pradhan, Balaram
Keyes, Robert F.
Smith, Brian C.
Abstract
Disclosed are compounds of the formula (I): wherein R1-R5122 are as defined in the specification, pharmaceutical salts thereof and stereoisomers thereof, and pharmaceutical compositions containing one or more of these compounds, salts, or stereoisomers thereof. Also disclosed is a method of treating a having a condition selected from the group consisting of chronic neuropathic pain, heart disease, suppressed immunity, and a disease of the liver, psoriasis, and cancer by administering to the subject having such a condition an effective amount of the compound or pharmaceutical composition.
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
80.
BASE-COVERED HIV-1 ENVELOPE ECTODOMAINS AND THEIR USE
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Kwong, Peter
Zhou, Tongqing
Olia, Adam
Rawi, Reda
Shah, Anita
Harris, Darcy
Chaudhary, Ridhi
Cheng, Cheng
Yang, Yongping
Abstract
Immunogens comprising a soluble HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and comprising modifications to introduce N-linked glycan sequons at the membrane-proximal base of the trimer, as well as methods of their use and production are disclosed. In several implementations, the immunogen can be used to elicit an immune response to HIV-1 in a subject.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Gros, Alena
Rosenberg, Steven A.
Abstract
Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Parchment, Ralph E.
Nguyen, Thu A.
Abstract
Provided are inserts (100) for preparing a cell culture chamber(s), or array of chambers, inside of histology cassettes that are suitable for three-dimensional multicellular growth of a cell or cells into spheroids, organoids, or other 3D structures, such that the resulting 3D multi-cellular structures are ready and suitable for histology processing without transfer to a different receptacle or container. Further embodiments of the invention provide methods of preparing at least one cell culture chamber using the inserts, systems for growing three-dimensional multicellular spheroids comprising culturing cells within a cell culture chamber prepared using the inserts, and systems for analyzing at least one cultured cell in vitro comprising culturing cells within a cell culture chamber prepared using the inserts.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Iyer, Malliga R.
Bhattacharjee, Pinaki
Cinar, Resat
Kunos, George
Dvoracsko, Szabolcs
Abstract
The application relates to compounds of the general Formula (I) which act as cannabinoid receptor modulators useful for the treatment of complications arising from metabolic, inflammatory and fibrotic disorders.
C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Schlom, Jeffrey
Hamilton, Duane H.
Palena, Claudia M.
Donahue, Renee N.
Abstract
The invention provides human immunogenic epitopes of HEMO and HHLA2 human endogenous retroviruses (HERVs), which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Gildersleeve, Jeffrey Charles
Temme, Joel Sebastian
Abstract
Antibodies and antigen-binding fragments thereof are provided that bind beta-1,6-poly-N-acetyl glucosamine (PNAG) that has been deacetylated in whole or part (dPNAG). Compositions and kits comprising these antibodies and antigen-binding fragment thereof are also provided. Such compositions can include, for example, diagnostic and therapeutic compositions. Methods of using these antibodies and antigen-binding fragments thereof are further provided. Such methods can include, for example, methods for preventing, diagnosing, and treating bacterial infections and associated biofilms characterized by PNAG and dPNAG.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Birukov, Konstantin
Eggerman, Thomas L.
Bocharov, Alexander V.
Renn, Cynthia L.
Abstract
Therapeutic agents, compositions, and methods are described for use in the treatment of acute or chronic pain, neuroinflammation, or conditions characterized by acute or chronic pain or neuroinflammation. The therapeutic agents comprise a synthetic amphipathic helical peptide capable of acting as a mimetic of apoA-I protein.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Levin, Noam
Yoseph, Rami
Cafri, Gal
Rosenberg, Steven A.
Abstract
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid. The TCRs may recognize G12D RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
United States of America, as represented by the Secretary, Department of Health and Human Services (USA)
Inventor
Beaucage, Serge L.
Grajkowski, Andrzej M.
Abstract
Disclosed herein are embodiments of a solid support suitable for synthesizing nucleic acid sequences. The solid support may have a structure according to Formula I, where CPG is controlled pore glass, and m, n, x, y, R1 and R2 are as defined herein.
Disclosed herein are embodiments of a solid support suitable for synthesizing nucleic acid sequences. The solid support may have a structure according to Formula I, where CPG is controlled pore glass, and m, n, x, y, R1 and R2 are as defined herein.
Disclosed herein are embodiments of a solid support suitable for synthesizing nucleic acid sequences. The solid support may have a structure according to Formula I, where CPG is controlled pore glass, and m, n, x, y, R1 and R2 are as defined herein.
Also disclosed are methods for making and using the solid support, kits including solid support, and a universal linker phosphoramidite suitable for use in the solid support.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C40B 50/18 - Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support using a particular method of attachment to the solid support
89.
METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR-REACTIVE T CELLS FROM TUMOR
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Gros, Alena
Rosenberg, Steven A.
Abstract
Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8+ T cells that express any one or more of TIM-3, LAG-3, 4-1BB, and PD-1 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
BATTELLE MEMORIAL INSTITUTE (USA)
Inventor
Morgan, Clint N.
Mauldin, Matthew R.
Jones, Jeremy
Abstract
A bat restraining device includes a capsule, a plunger, and a base. The capsule includes top and bottom shells, at least one of which includes a longitudinally extending concave inner surface forming a cavity between the top and bottom shells. The top and bottom shells are removably coupled together, spaced apart along at least a portion of their length. At least a portion of a proximal end of the plunger is configured and disposed to slide in a longitudinal direction in a proximal end of the cavity formed between the top and bottom shells. One of the bottom shell and the plunger is secured with the base, while the other of the bottom shell and the plunger is movable in the longitudinal direction relative to the base.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (USA)
Inventor
Kulam Najmudeen, Magdoom Mohamed
Basser, Peter J.
Komlosh, Michal E.
Abstract
Diffusion sensitizing gradient pulse pairs are prescribed in a manner to mitigate effects of concomitant gradient artifacts. Measured MR signals generated by applying a plurality of diffusion sensitizing gradient matrices are obtained and processed to determine a second order mean diffusion tensor and a fourth order covariance tensor. Quantities derived from these tensors are measured and mapped within an imaging volume which describe features of diffusion anisotropy and heterogeneity within each imaging voxel.
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
G01R 33/24 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance for measuring direction or magnitude of magnetic fields or magnetic flux
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Vizcardo, Raul E.
Islam, Sm Rafiqul
Tamaoki, Naritaka
Maeda, Takuya
Restifo, Nicholas P.
Abstract
Disclosed are methods for reprogramming cancer-reactive T cells into iPSC cells as well as methods utilizing such cells for the identification of cancer-antigen specific TCRs and the treatment of cancer.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Ho, Mitchell
Thiele, Carol J.
Li, Nan
Nguyen, Hong Ha Rosa
Kaplan, Rosandra N.
Abstract
Optimized chimeric antigen receptors (CARs) targeting glypican-2 (GPC2) and having a CD28 hinge region and a CD28 transmembrane domain are described. The antigen-binding domain of the disclosed CARs is derived from GPC2-specific antibody CT3 or humanized versions thereof. The optimized CARs also include an intracellular co-stimulatory domain and an intracellular signaling domain. Immune cells or induced pluripotent stem cells expressing the optimized CARs can be used to treat GPC2-positive solid tumors, such as neuroblastoma.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Levin, Noam
Lowery, Iii, Frank J.
Parkhurst, Maria R.
Rosenberg, Steven A.
Abstract
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine. The TCRs may recognize G12V RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Henderson, Mark J.
Ronzetti, Michael H.
Baljinnyam, Bolormaa
Sanchez, Tino W.
Michael, Samuel G.
Owens, Ashley E.
Simeonov, Anton
Abstract
The disclosure provides methods for carrying out Real Time Cellular Thermal Shift Assays (RT-CETSA). Also provided are molecular constructs and protein constructs for use in such assays and devices suitable for carrying out such assays.
The United States of America,as represented by the Secretary,Department of Health and Human Services (USA)
Inventor
Lowery, Iii, Frank J.
Krishna, Sri
Robbins, Paul F.
Rosenberg, Steven A.
Altan-Bonnet, Gregoire Y.
Abstract
Disclosed are methods of obtaining a cell population enriched for T cells with a phenotype, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample of a patient; (b) specifically selecting T cells with a phenotype comprising markers CD3+, CD39−, and CD69− from the bulk population; and (c) separating the cells selected in (b) from cells which lack the phenotype to obtain a cell population enriched for T cells with the phenotype. Related methods of treating or preventing cancer, methods of selecting a therapy for a cancer patient, and methods for predicting the clinical response to immunotherapy in a cancer patient are also disclosed. Isolated or purified cell population obtained according to the methods and related pharmaceutical compositions are also disclosed.
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
97.
FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (USA)
Inventor
Marugan, Juan J.
Southall, Noel T.
Ferrer, Marc
Henderson, Mark J.
Wilson, Kenneth J.
Agoulnik, Alexander I.
Myhr, Courney B.
Esteban-Lopez, Maria
Barnaeva, Elena
Hu, Xin
Ye, Wenjuan
Agoulnik, Irina
Abstract
Disclosed is a compound of formula (I), in which R1, R2, R3, R4, R5, X1, X2, X3, X4, and X5 are described herein. The small molecule compounds of formula (I) activate the functional activity of relaxin family peptide receptor 2 (RXFP2), thereby providing therapeutic treatments for a variety of disorders, such as a bone disorder, hypogonadism, cryptorchidism, polycystic ovary syndrome, cancer, infertility, or an ocular wound.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Alam, Md Masud
Yang, De
Abstract
Methods are disclosed herein for treating a cancer in a subject. Embodiments of the methods include administering to the subject a therapeutically effective amount of a combination therapy comprising a TLR4 agonist (such as HMGN1), a TLR2/6 agonist (such as FSL-1), and a checkpoint inhibitor. Optionally, the combination therapy administered to the subject can include a STING agonist (such as cGAMP or c-di-GMP). In some embodiments, the checkpoint inhibitor is a PD-L1 inhibitor, a PD-1 inhibitor, a TNFR-2 inhibitor, or a CTLA-4 inhibitor. In some embodiments, the cancer is a colorectal cancer, a kidney cancer, or melanoma.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventor
Tan, Joshua Hoong Yu
Dacon, Cherrelle
Abstract
Disclosed are monoclonal antibodies and antigen binding fragments that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
KUROME THERAPEUTICS, INC. (USA)
Inventor
Hoyt, Scott, Bryan
Thomas, Craig, Joseph
Tawa, Gregory, J.
Rosenbaum, Jan, Susan
Gracia Maldonado, Gabriel
Starczynowski, Daniel, T.
Abstract
Some embodiments of the disclosure include disclosed compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the disclosed compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the disclosed IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.